Switch From Tysabri to Moderate-efficacy DMTs Linked to Worse Disability
News
Patients with multiple sclerosis (MS) switching from Tysabri (natalizumab) to moderate-efficacy disease-modifying therapies (DMTs) are at a higher risk of showing signs of MS activity and experiencing disability progression ... Read more